https://orcid.org/0000-0002-0460-6427
References
- Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327:464–477.
- de Moraes Hungria VT, Martínez-Baños DM, Peñafiel CR, et al. Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016. Br J Haematol. 2020;188:383–393.
- Tarín-Arzaga L, Arredondo-Campos D, Martínez-Pacheco V, et al. Impact of the affordability of novel agents in patients with multiple myeloma: real-world data of current clinical practice in Mexico. Cancer. 2018;124:1946–1953.
- Riva E, Schütz N, Peña C, et al. Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Múltiple). Ann Hematol. 2020;99:1025–1030.
- Curado MP, Oliveira MM, Silva DRM, et al. Epidemiology of multiple myeloma in 17 Latin American countries: an update. Cancer Med. 2018;7:2101–2108.
- Kumar SK, Callander NS, Adekola K, et al. Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:1685–1717.
- Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–3420.
- Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–2869.
- Garrido DI, Bove V, Matosas V, et al. Comparative survival analysis using the International Stratification Score (ISS) in newly-diagnosed multiple myeloma in the Uruguayan population. Med Pharm Rep. 2021;94:48–52.
- Schütz NP, Ochoa P, Duarte P, et al. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A retrospective cohort study from Grupo Argentino de Mieloma Múltiple. Hematol Oncol. 2020;38:363–371.
- Bojalil-Alvarez L, Gertz MA, Garcia-Villaseñor E, et al. Long term survival in multiple myeloma: a single institution experience in underprivileged circumstances. Leuk Lymphoma. 2021;63(5):1–6.
- Crusoe EQ, Higashi F, Martinez G, et al. Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation. Hematol Transfus Cell Ther. 2020;42:118–124.
- Hungria V, Martínez-Baños DM, Mateos MV, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone versus standard of care in Latin America for transplant-ineligible newly diagnosed multiple myeloma: propensity score matching analysis. Adv Ther. 2020;37:4996–5009.
- Ruiz-Argüelles GJ, Gómez-Almaguer D. Lessons learned treating patients with multiple myeloma in resource-constrained settings. Curr Hematol Malig Rep. 2021;16(1):40–44.